Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OrienX 010

Next Previous
Search
Drug Profile

OrienX 010

Alternative Names: OrienX010; OrienX10; Recombinant hGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; Recombinant hGM-CSF HSV - OrienGene Biotechnology; rhGM-CSF Herpes Simplex Virus - OrienGene Biotechnology; rhGM-CSF HSV - OrienGene Biotechnology

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OrienGene Biotechnology
  • Developer Beijing Bozhiyin T&S; OrienGene Biotechnology; START Shanghai
  • Class Cancer vaccines; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • No development reported Solid tumours

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, In the elderly, In adults) in China (Intratumoural, Injection)
  • 02 Jun 2023 Adverse events and efficacy data from a phase-I trial in Malignant melanoma presented at the presented at 59th Annual Meeting of American Society of Clinical Oncology (ASCO-2023)
  • 09 Sep 2022 Efficacy and adverse events data from a phase I trial in Malignant melanoma presented at the 47th European Society for Medical Oncology Congress (ESMO-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top